For other MAbs outside the IBD setting, comprehensive studies showing the links among MAb concentrations, loss of response, and outcomes are not available and the recommendations for patient management based on serum monitoring of MAb concentrations is less clear, although it seems that the TNF-α inhibitor experience can be translated to other areas (21, 22). This evidence concerns the gene TNF and inflammatory bowel disease.